Imatinib therapy in chronic myeloid leukemia
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference57 articles.
1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells;Druker;Nat Med,1996
2. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells;Deininger;Blood,1997
3. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis;Gambacorti-Passerini;Blood Cells Mol Dis,1997
4. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia;Druker;J Clin Invest,2000
5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Biomarkers for Determining the Prognosis of CML;Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia;2016
2. Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level;Bioorganic & Medicinal Chemistry;2014-01
3. Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase;Pharmacology;2011
4. A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times;Therapeutic Drug Monitoring;2009-10
5. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia;Leukemia;2009-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3